Supplementary Methods, Table S1, Figures S1 - S8 from PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers

Supplementary Table S1. T cell receptor (TCR) Vβ repertoire usage in CD3+CD4+ T cells from tumor-bearing and non tumor-bearing mice. Supplementary Figure S1. Pancytopenia in D1T286A-reconstituted mice, immnuphenotype of PRMT5-reconstituted mice and TCR clonality of D1T286A+PRMT5 mice. Supplementary Figure S2 Phenotype of the D1T286A+PRMT5 lymphoma and the D1T286A and PRMT5 triggered lymphoma is 100% transplantable. Supplementary Figure S3. PRMT5 is required for leukemia driven by MLL-AF9. Supplementary Figure S4. Cyclin D1T286A triggers T/B-cell lymphoma in p53 dependent way. Supplementary Figure S5. Confirmation of Cyclin D1T286A/PRMT5 expression and p53me2 antibody. Supplementary Figure S6. Cyclin D1T286A/CDK4 phosphorylation of MEP50 increases PRMT5-dependent methylation of p53. Supplementary Figure S7. Effect of PRMT5 and D1T286A on the Apaf1, Cdkn1a, Bax and Pmaip1 promoters. Supplementary Figure S8. PRMT5 and/or H4R3 are elevated in primary human cancers.